Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - SUNOVION CNS DEVELOPMENT CANADA ULCv436472_ex99-2.htm
EX-99.3 - EXHIBIT 99.3 - SUNOVION CNS DEVELOPMENT CANADA ULCv436472_ex99-3.htm
EX-99.1 - EXHIBIT 99.1 - SUNOVION CNS DEVELOPMENT CANADA ULCv436472_ex99-1.htm
EX-99.4 - EXHIBIT 99.4 - SUNOVION CNS DEVELOPMENT CANADA ULCv436472_ex99-4.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 19, 2016

  

Cynapsus Therapeutics Inc.

(Exact name of registrant as specified in its charter)

  

Canada   001-37426   98-1226819

(State or other jurisdiction

of incorporation)

  (Commission File Number)   (I.R.S. Employer Identification No.)

 

828 Richmond Street West,

Toronto, Ontario, Canada

(Address of principal executive offices)

 

M6J 1C9

(Zip Code)

 

Registrant’s telephone number, including area code: 416-703-2449

 

N/A

(Former name or former address, if changed since last report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01Other Events.

 

Cynapsus Therapeutics Inc.’s (the “Company”) 2016 annual and special meeting of shareholders will be held on Tuesday, May 10, 2016. Certain materials mailed by the Company to its shareholders on April 19, 2016 in connection with such meeting are filed under Item 9.01 herewith.

 

Item 9.01Financial Statements and Exhibits.

 

d)Exhibits

 

The following exhibits are filed herewith:

 

Exhibit
No.

 

Description

99.1   Notice of Annual and Special Meeting of Shareholders and Management Information Circular dated April 4, 2016
99.2   Voting Instruction Form
99.3   Form of Proxy
99.4   Request for Financial Statements

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CYNAPSUS THERAPEUTICS INC.
       
Date: April 19, 2016 By: /s/ Andrew Williams  
  Name: Andrew Williams  
  Title: Chief Operating Officer and  
    Chief Financial Officer  

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

99.1   Notice of Annual and Special Meeting of Shareholders and Management Information Circular dated April 4, 2016
99.2   Voting Instruction Form
99.3   Form of Proxy
99.4   Request for Financial Statements